表紙:ワクチンの世界市場 (2021-2027年):市場予測 (年齢・疾患・技術別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア
市場調査レポート
商品コード
1008675

ワクチンの世界市場 (2021-2027年):市場予測 (年齢・疾患・技術別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア

Vaccines Market Size By Age Group, By Disease, By Technology, COVID19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 210 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.65円
ワクチンの世界市場 (2021-2027年):市場予測 (年齢・疾患・技術別)・COVID-19の影響・地域的展望・成長の潜在性・価格動向・市場シェア
出版日: 2021年05月28日
発行: Global Market Insights Inc.
ページ情報: 英文 210 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

新型コロナウイルス感染症 (COVID-19) の世界的流行、ワクチン接種に対する意識の高まり、生ワクチン技術に関する多くのメリットなどの要因が世界のワクチン市場の成長を推進する見通しです。

年齢別では、小児の部門が2020年に約55%のシェアを獲得し、今後数年も着実な成長を示すと予測されています。政府プログラム下で定期予防接種のニーズが高まっているため、製品の消費が促進されています。また、疾患別では、COVID-19の部門が前例のないシェアの拡大を示しており、現在もその傾向が続いています。

当レポートでは、世界のワクチンの市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、償還シナリオ、技術動向、市場規模の推移・予測、年齢・疾患・技術・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 産業考察

  • 産業の分類
  • 産業情勢
  • 産業への影響要因
    • 成長要因
    • 潜在的リスク&課題
  • 成長の潜在性
  • COVID-19:影響分析
  • 技術情勢
  • 規制状況
  • パイプライン分析
  • 償還シナリオ
  • ポーター分析
  • 企業マトリックス
  • PESTEL分析

第4章 市場分析・予測:年齢層別

  • 小児
  • 大人

第5章 市場分析・予測:疾患別

  • 肝炎
  • 肺炎球菌感染症
  • DTP
  • デング熱
  • インフルエンザ
  • ヒトパピローマウイルス
  • 髄膜炎菌性疾患
  • ポリオ
  • ロタウイルス
  • COVID-19
  • その他

第6章 市場分析・予測:技術別

  • 共役ワクチン
  • 生ワクチン
  • 不活化ワクチン
  • 組換えワクチン
  • トキソイドワクチン
  • その他

第7章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 企業プロファイル

  • Competitive dashboard, 2020
  • Abbott Laboratories
  • Astellas Pharma, Inc.
  • AstraZeneca
  • Serum Institute of India Pvt. Ltd
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Novavax, Inc.
  • Pfizer
  • Sanofi Pasteur
図表

Data Tables

  • TABLE 1. Vaccines industry 360 degree synopsis
  • TABLE 2. Global vaccines market, 2016 - 2020 (USD Million)
  • TABLE 3. Global vaccines market, 2021 - 2027 (USD Million)
  • TABLE 4. Global vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 5. Global vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 6. Global vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 7. Global vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 8. Global vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 9. Global vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 10. Global vaccines market, by region, 2016 - 2020 (USD Million)
  • TABLE 11. Global vaccines market, by region, 2021 - 2027 (USD Million)
  • TABLE 12. Industry impact forces
  • TABLE 13. Pediatric market size, by region, 2016 - 2020 (USD Million)
  • TABLE 14. Pediatric market size, by region, 2021 - 2027 (USD Million)
  • TABLE 15. Adult market size, by region, 2016 - 2020 (USD Million)
  • TABLE 16. Adult market size, by region, 2021 - 2027 (USD Million)
  • TABLE 17. Conjugate market size, by region, 2016 - 2020 (USD Million)
  • TABLE 18. Conjugate market size, by region, 2021 - 2027 (USD Million)
  • TABLE 19. Live acting market size, by region, 2016 - 2020 (USD Million)
  • TABLE 20. Live acting market size, by region, 2021 - 2027 (USD Million)
  • TABLE 21. Inactivated market size, by region, 2016 - 2020 (USD Million)
  • TABLE 22. Inactivated market size, by region, 2021 - 2027 (USD Million)
  • TABLE 23. Recombinant market size, by region, 2016 - 2020 (USD Million)
  • TABLE 24. Recombinant market size, by region, 2021 - 2027 (USD Million)
  • TABLE 25. Toxoid market size, by region, 2016 - 2020 (USD Million)
  • TABLE 26. Toxoid market size, by region, 2021 - 2027 (USD Million)
  • TABLE 27. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 28. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 29. Cancer market size, by region, 2016 - 2020 (USD Million)
  • TABLE 30. Cancer market size, by region, 2021 - 2027 (USD Million)
  • TABLE 31. Hepatitis market size, by region, 2016 - 2020 (USD Million)
  • TABLE 32. Hepatitis market size, by region, 2021 - 2027 (USD Million)
  • TABLE 33. Pneumococcal disease market size, by region, 2016 - 2020 (USD Million)
  • TABLE 34. Pneumococcal disease market size, by region, 2021 - 2027 (USD Million)
  • TABLE 35. DTP market size, by region, 2016 - 2020 (USD Million)
  • TABLE 36. DTP market size, by region, 2021 - 2027 (USD Million)
  • TABLE 37. Dengue inhibitors market size, by region, 2016 - 2020 (USD Million)
  • TABLE 38. Dengue market size, by region, 2021 - 2027 (USD Million)
  • TABLE 39. Influenza market size, by region, 2016 - 2020 (USD Million)
  • TABLE 40. Influenza market size, by region, 2021 - 2027 (USD Million)
  • TABLE 41. Human papillomavirus market size, by region, 2016 - 2020 (USD Million)
  • TABLE 42. Human papillomavirus market size, by region, 2021 - 2027 (USD Million)
  • TABLE 43. Meningococcal disease market size, by region, 2016 - 2020 (USD Million)
  • TABLE 44. Meningococcal disease market size, by region, 2021 - 2027 (USD Million)
  • TABLE 45. Polio market size, by region, 2016 - 2020 (USD Million)
  • TABLE 46. Polio market size, by region, 2021 - 2027 (USD Million)
  • TABLE 47. Rotavirus market size, by region, 2016 - 2020 (USD Million)
  • TABLE 48. Rotavirus market size, by region, 2021 - 2027 (USD Million)
  • TABLE 49. COVID-19 market size, by region, 2016 - 2020 (USD Million)
  • TABLE 50. COVID-19 market size, by region, 2021 - 2027 (USD Million)
  • TABLE 51. Others market size, by region, 2016 - 2020 (USD Million)
  • TABLE 52. Others market size, by region, 2021 - 2027 (USD Million)
  • TABLE 53. North America market, by country, 2016 - 2020 (USD Million)
  • TABLE 54. North America market, by country, 2021 - 2027 (USD Million)
  • TABLE 55. North America vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 56. North America vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 57. North America vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 58. North America vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 59. North America vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 60. North America vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 61. U.S. vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 62. U.S. vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 63. U.S. vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 64. U.S. vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 65. U.S. vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 66. U.S. vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 67. Canada vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 68. Canada vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 69. Canada vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 70. Canada vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 71. Canada vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 72. Canada vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 73. Europe market, by country, 2016 - 2020 (USD Million)
  • TABLE 74. Europe market, by country, 2021 - 2027 (USD Million)
  • TABLE 75. Europe vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 76. Europe vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 77. Europe vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 78. Europe vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 79. Europe vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 80. Europe vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 81. Germany vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 82. Germany vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 83. Germany vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 84. Germany vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 85. Germany vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 86. Germany vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 87. UK vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 88. UK vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 89. UK vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 90. UK vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 91. UK vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 92. UK vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 93. France vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 94. France vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 95. France vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 96. France vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 97. France vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 98. France vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 99. Italy vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 100. Italy vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 101. Italy vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 102. Italy vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 103. Italy vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 104. Italy vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 105. Spain vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 106. Spain vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 107. Spain vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 108. Spain vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 109. Spain vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 110. Spain vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 111. Russia vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 112. Russia vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 113. Russia vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 114. Russia vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 115. Russia vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 116. Russia vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 117. Asia Pacific market size, by country, 2016 - 2020 (USD Million)
  • TABLE 118. Asia Pacific market size, by country, 2021 - 2027 (USD Million)
  • TABLE 119. Asia Pacific vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 120. Asia Pacific vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 121. Asia Pacific vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 122. Asia Pacific vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 123. Asia Pacific vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 124. Asia Pacific vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 125. Japan vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 126. Japan vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 127. Japan vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 128. Japan vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 129. Japan vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 130. Japan vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 131. China vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 132. China vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 133. China vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 134. China vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 135. China vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 136. China vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 137. India vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 138. India vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 139. India vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 140. India vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 141. India vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 142. India vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 143. Australia vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 144. Australia vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 145. Australia vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 146. Australia vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 147. Australia vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 148. Australia vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 149. South Korea vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 150. South Korea vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 151. South Korea vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 152. South Korea vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 153. South Korea vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 154. South Korea vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 155. Latin America market size, by country, 2016 - 2020 (USD Million)
  • TABLE 156. Latin America market size, by country, 2021 - 2027 (USD Million)
  • TABLE 157. Latin America vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 158. Latin America vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 159. Latin America vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 160. Latin America vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 161. Latin America vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 162. Latin America vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 163. Brazil vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 164. Brazil vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 165. Brazil vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 166. Brazil vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 167. Brazil vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 168. Brazil vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 169. Mexico vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 170. Mexico vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 171. Mexico vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 172. Mexico vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 173. Mexico vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 174. Mexico vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 175. Argentina vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 176. Argentina vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 177. Argentina vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 178. Argentina vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 179. Argentina vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 180. Argentina vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 181. MEA market size, by country, 2016 - 2020 (USD Million)
  • TABLE 182. MEA market size, by country, 2021 - 2027 (USD Million)
  • TABLE 183. MEA vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 184. MEA vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 185. MEA vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 186. MEA vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 187. MEA vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 188. MEA vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 189. South Africa vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 190. South Africa vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 191. South Africa vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 192. South Africa vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 193. South Africa vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 194. South Africa vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 195. Saudi Arabia vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 196. Saudi Arabia vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 197. Saudi Arabia vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 198. Saudi Arabia vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 199. Saudi Arabia vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 200. Saudi Arabia vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 201. UAE vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 202. UAE vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 203. UAE vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 204. UAE vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 205. UAE vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 206. UAE vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 207. Qatar Arabia vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 208. Qatar Arabia vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 209. Qatar Arabia vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 210. Qatar Arabia vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 211. Qatar vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 212. Qatar vaccines market, by technology, 2021 - 2027 (USD Million)
  • TABLE 213. Egypt vaccines market, by age group, 2016 - 2020 (USD Million)
  • TABLE 214. Egypt vaccines market, by age group, 2021 - 2027 (USD Million)
  • TABLE 215. Egypt vaccines market, by disease, 2016 - 2020 (USD Million)
  • TABLE 216. Egypt vaccines market, by disease, 2021 - 2027 (USD Million)
  • TABLE 217. Egypt vaccines market, by technology, 2016 - 2020 (USD Million)
  • TABLE 218. Egypt vaccines market, by technology, 2021 - 2027 (USD Million)

Charts & Figures

  • FIG.1. Global vaccines industry 360 degree synopsis
  • FIG.2. Industry segmentation
  • FIG.3. Growth potential analysis, by age group
  • FIG.4. Growth potential analysis, by disease
  • FIG.5. Growth potential analysis, by technology
  • FIG.6. Porter's analysis
  • FIG.7. Company share analysis, 2020
  • FIG.8. PESTEL analysis
  • FIG.9. Competitive dashboard, 2020
目次
Product Code: 2186

Global vaccines market forecast over 2021-2027 will be driven by higher awareness about vaccinations, numerous advantages related to live vaccine technology, the ongoing fight against COVID-19 across the globe. A vaccine is a biological substance designed to guard humans from infections caused by viruses and bacteria. These are also termed as immunizations since they take advantage of the ability of the natural immune system to prevent infectious disease.

The market for vaccines has a wide range of factors, including the complexity of assessing as well as understanding procurement and pricing. The industry is bifurcated in terms of product, disease, technology and regional landscape.

With respect to product, the vaccines market is divided into adult and pediatric consumers. In 2020, the pediatric segment gathered a global market share of around 55% and will continue to exhibit steady growth over the coming years. The growing need for routine immunization under government programs will aid the product consumption.

The most effective as well as a safe way to protect children from transmittable diseases is by vaccination. These are meant to safeguard the health of children by preventing them from contracting severe infectious diseases. Vaccine schedules suggested by organizations and agencies, such as the CDC, the American Academy of Pediatrics, and the American Academy of Family Physicians and the American Academy of Pediatrics cover up to 14 different diseases.

Vaccines market share is segmented into COVID-19, human papilloma virus, rotavirus, hepatitis, polio, meningococcal disease, cancer, influenza, dengue, DTP, pneumococcal disease and other diseases. The industry share from COVID-19 disease segment has seen unprecedented rise and still continues to do so. Factors such as the need for better effective vaccine, and millions of vaccine candidates will strengthen the segment potential.

At present, nearly all the coronavirus vaccines available worldwide have proven to be effective and safe at preventing COVID-19. Getting inoculated will also protect the people around, mainly those who are at a much higher risk for contacting severe infection from COVID-19.

In terms of technology, the vaccines market is categorized into toxoid, live, inactivated, recombinant, conjugate, and others. Among these, the live technology segment held more than 20% share in the global vaccines market. This growth is driven by the capability of these vaccines to impart immunity for a longer time period.

On the regional front, factors such as presence of suitable reimbursement policies in the U.S., high adoption and hospitalization rate, awareness rate about vaccination, and presence of numerous eminent pharmaceutical and biopharmaceutical companies will expand the vaccines market in North America.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates and working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle east & Africa
  • 1.3 Forecast calculations
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Vaccines industry 360 degree synopsis, 2016 - 2027
    • 2.1.1 Business trends
    • 2.1.2 Age group trends
    • 2.1.3 Disease trends
    • 2.1.4 Technology trends
    • 2.1.5 Regional trends

Chapter 3 Vaccines Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing need for vaccination against coronavirus infection
      • 3.3.1.2 Increasing government funding for vaccine development pertaining to COVID-19 situation
      • 3.3.1.3 Increasing disease prevalence in underdeveloped countries
      • 3.3.1.4 Growing incidence of cancer & HIV in Asia Pacific
      • 3.3.1.5 Increasing vaccines R&D in developed nations
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 High cost of vaccine storage and transportation
      • 3.3.2.2 Stringent regulations for the approval of vaccines in developed nations
      • 3.3.2.3 Drug-development hurdles
  • 3.4 Growth potential analysis
    • 3.4.1 By age group
    • 3.4.2 By disease
    • 3.4.3 By technology
  • 3.5 COVID-19 impact analysis
  • 3.6 Technology landscape
  • 3.7 Regulatory landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Asia Pacific
  • 3.8 Pipeline analysis
  • 3.9 Reimbursement scenario
  • 3.10 Porter's analysis
  • 3.11 Company matrix analysis, 2020
  • 3.12 PESTEL analysis

Chapter 4 Vaccines Market, By Age Group

  • 4.1 Key segment trends
  • 4.2 Pediatric
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Adult
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Vaccines Market, By Disease

  • 5.1 Key segment trends
  • 5.2 Cancer
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Hepatitis
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.4 Pneumococcal disease
    • 5.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.5 DTP
    • 5.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.6 Dengue
    • 5.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.7 Influenza
    • 5.7.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.8 Human papilloma virus
    • 5.8.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.9 Meningococcal disease
    • 5.9.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.10 Polio
    • 5.10.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.11 Rotavirus
    • 5.11.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.12 COVID-19
    • 5.12.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.13 Others
    • 5.13.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Vaccines Market, By Technology

  • 6.1 Key segment trends
  • 6.2 Conjugate
    • 6.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.3 Live
    • 6.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.4 Inactivated
    • 6.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.5 Recombinant
    • 6.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.6 Toxoid
    • 6.6.1 Market size, by region, 2016 - 2027 (USD Million)
  • 6.7 Others
    • 6.7.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 7 Vaccines Market, By Region

  • 7.1 Key regional trends
  • 7.2 North America
    • 7.2.1 Market size by country, 2016 - 2027 (USD Million)
    • 7.2.2 Market size by age group, 2016 - 2027 (USD Million)
    • 7.2.3 Market size by disease, 2016 - 2027 (USD Million)
    • 7.2.4 Market size by technology, 2016 - 2027 (USD Million)
    • 7.2.5 U.S.
      • 7.2.5.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.2.5.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.2.5.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.2.6 Canada
      • 7.2.6.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.2.6.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.2.6.3 Market size by technology, 2016 - 2027 (USD Million)
  • 7.3 Europe
    • 7.3.1 Market size by country, 2016 - 2027 (USD Million)
    • 7.3.2 Market size by age group, 2016 - 2027 (USD Million)
    • 7.3.3 Market size by disease, 2016 - 2027 (USD Million)
    • 7.3.4 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.5 Germany
      • 7.3.5.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.5.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.5.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.6 UK
      • 7.3.6.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.6.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.6.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.7 France
      • 7.3.7.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.7.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.7.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.8 Italy
      • 7.3.8.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.8.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.8.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.9 Spain
      • 7.3.9.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.9.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.9.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.3.10 Russia
      • 7.3.10.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.3.10.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.3.10.3 Market size by technology, 2016 - 2027 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Market size by country, 2016 - 2027 (USD Million)
    • 7.4.2 Market size by age group, 2016 - 2027 (USD Million)
    • 7.4.3 Market size by disease, 2016 - 2027 (USD Million)
    • 7.4.4 Market size by technology, 2016 - 2027 (USD Million)
    • 7.4.5 Japan
      • 7.4.5.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.4.5.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.4.5.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.4.6 China
      • 7.4.6.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.4.6.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.4.6.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.4.7 India
      • 7.4.7.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.4.7.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.4.7.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.4.8 Australia
      • 7.4.8.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.4.8.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.4.8.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.4.9 South Korea
      • 7.4.9.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.4.9.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.4.9.3 Market size by technology, 2016 - 2027 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Market size by country, 2016 - 2027 (USD Million)
    • 7.5.2 Market size by age group, 2016 - 2027 (USD Million)
    • 7.5.3 Market size by disease, 2016 - 2027 (USD Million)
    • 7.5.4 Market size by technology, 2016 - 2027 (USD Million)
    • 7.5.5 Brazil
      • 7.5.5.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.5.5.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.5.5.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.5.6 Mexico
      • 7.5.6.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.5.6.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.5.6.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.5.7 Argentina
      • 7.5.7.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.5.7.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.5.7.3 Market size by technology, 2016 - 2027 (USD Million)
  • 7.6 Middle East & Africa (MEA)
    • 7.6.1 Market size by country, 2016 - 2027 (USD Million)
    • 7.6.2 Market size by age group, 2016 - 2027 (USD Million)
    • 7.6.3 Market size by disease, 2016 - 2027 (USD Million)
    • 7.6.4 Market size by technology, 2016 - 2027 (USD Million)
    • 7.6.5 South Africa
      • 7.6.5.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.6.5.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.6.5.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.6.6 Saudi Arabia
      • 7.6.6.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.6.6.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.6.6.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.6.7 UAE
      • 7.6.7.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.6.7.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.6.7.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.6.8 Qatar
      • 7.6.8.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.6.8.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.6.8.3 Market size by technology, 2016 - 2027 (USD Million)
    • 7.6.9 Egypt
      • 7.6.9.1 Market size by age group, 2016 - 2027 (USD Million)
      • 7.6.9.2 Market size by disease, 2016 - 2027 (USD Million)
      • 7.6.9.3 Market size by technology, 2016 - 2027 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Competitive dashboard, 2020
  • 8.2 Abbott Laboratories
    • 8.2.1 Business overview
    • 8.2.2 Financial data
    • 8.2.3 Product landscape
    • 8.2.4 Strategic outlook
    • 8.2.5 SWOT analysis
  • 8.3 Astellas Pharma, Inc.
    • 8.3.1 Business overview
    • 8.3.2 Financial data
    • 8.3.3 Product landscape
    • 8.3.4 Strategic outlook
    • 8.3.5 SWOT analysis
  • 8.4 AstraZeneca
    • 8.4.1 Business overview
    • 8.4.2 Financial data
    • 8.4.3 Product landscape
    • 8.4.4 Strategic outlook
    • 8.4.5 SWOT analysis
  • 8.5 Serum Institute of India Pvt. Ltd
    • 8.5.1 Business overview
    • 8.5.2 Financial data
    • 8.5.3 Product landscape
    • 8.5.4 Strategic outlook
    • 8.5.5 SWOT analysis
  • 8.6 CSL Limited
    • 8.6.1 Business overview
    • 8.6.2 Financial data
    • 8.6.3 Product landscape
    • 8.6.4 Strategic outlook
    • 8.6.5 SWOT analysis
  • 8.7 Emergent BioSolutions, Inc.
    • 8.7.1 Business overview
    • 8.7.2 Financial data
    • 8.7.3 Product landscape
    • 8.7.4 Strategic outlook
    • 8.7.5 SWOT analysis
  • 8.8 GlaxoSmithKline
    • 8.8.1 Business overview
    • 8.8.2 Financial data
    • 8.8.3 Product landscape
    • 8.8.4 Strategic outlook
    • 8.8.5 SWOT analysis
  • 8.9 Johnson & Johnson
    • 8.9.1 Business overview
    • 8.9.2 Financial data
    • 8.9.3 Product landscape
    • 8.9.4 Strategic outlook
    • 8.9.5 SWOT analysis
  • 8.10 Merck & Co.
    • 8.10.1 Business overview
    • 8.10.2 Financial data
    • 8.10.3 Product landscape
    • 8.10.4 Strategic outlook
    • 8.10.5 SWOT analysis
  • 8.11 Novavax, Inc.
    • 8.11.1 Business overview
    • 8.11.2 Financial data
    • 8.11.3 Product landscape
    • 8.11.4 Strategic outlook
    • 8.11.5 SWOT analysis
  • 8.12 Pfizer
    • 8.12.1 Business overview
    • 8.12.2 Financial data
    • 8.12.3 Product landscape
    • 8.12.4 Strategic outlook
    • 8.12.5 SWOT analysis
  • 8.13 Sanofi Pasteur
    • 8.13.1 Business overview
    • 8.13.2 Financial data
    • 8.13.3 Product landscape
    • 8.13.4 Strategic outlook
    • 8.13.5 SWOT analysis